Prelude Therapeutics
PRLD
59 hedge funds and large institutions have $26.9M invested in Prelude Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 24 reducing their positions, and 7 closing their positions.
5% less funds holding
Funds holding: 62 → 59 (-3)
21% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 24
20.89% less ownership
Funds ownership: 76.25% → 55.36% (-21%)
34% less capital invested
Capital invested by funds: $41M → $26.9M (-$14.1M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Boxer Capital Management
San Diego,
California
|
+$373K |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$159K |
| 3 |
MG
Marex Group
London,
|
+$52.5K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$41K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$31.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$850K |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$630K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$498K |
| 4 |
Millennium Management
New York
|
-$295K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$141K |
PRLD Hedge Fund Activity: Q1 2025 in Review
59 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q1 2025, worth a combined $26.9M — down 34% from $41M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PRLD and 4 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 19 added.
The largest buyer was Boxer Capital Management, adding an estimated $373K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $850K sold.
- 59 institutional investors held Prelude Therapeutics (PRLD) as of Q1 2025, down from 62 in Q4 2024.
- Funds reported $26.9M of Prelude Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
- 4 funds opened new Prelude Therapeutics positions in Q1 2025 and 7 closed out, a net change of -3 holders.
- The largest Prelude Therapeutics buyer in Q1 2025 was Boxer Capital Management, an estimated $373K added.
- The largest Prelude Therapeutics seller in Q1 2025 was Jacobs Levy Equity Management, an estimated $850K sold.
Based on aggregated 13F filings for Q1 2025.